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Despite evident regulatory roles of heparan sulfate (HS) saccharides in numerous biological
processes, definitive information on the bioactive sequences of these polymers is lacking,
with only a handful of natural structures sequenced to date. Here, we develop a “Shotgun” Ion
Mobility Mass Spectrometry Sequencing (SIMMS2) method in which intact HS saccharides
are dissociated in an ion mobility mass spectrometer and collision cross section values of
fragments measured. Matching of data for intact and fragment ions against known values for
36 fully defined HS saccharide structures (from di- to decasaccharides) permits unambiguous
sequence determination of validated standards and unknown natural saccharides, notably
including variants with 3O-sulfate groups. SIMMS2 analysis of two fibroblast growth factor-
inhibiting hexasaccharides identified from a HS oligosaccharide library screen demonstrates
that the approach allows elucidation of structure-activity relationships. SIMMS2 thus over-
comes the bottleneck for decoding the informational content of functional HS motifs which is
crucial for their future biomedical exploitation.
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Glycosaminoglycans (GAGs) are linear sulfated poly-saccharides which constitute some of the most negativelycharged biopolymers in nature. The heparan sulfate (HS)
family of GAGs are linear polysaccharides found on the cell
surface and in the extracellular matrix. GAGs are attached to core
proteins in the form of proteoglycans (PGs), and exhibit great
diversity in chain length and degree of sulfation patterns, creating
enormous diversity for informational cues. HS chains are essen-
tial for life and orchestrate numerous biological processes
including; cell migration, inflammation, anticoagulation, angio-
genesis, and tumor metastasis1. It is generally believed that dis-
tinct structural motifs along the linear sequence of these
polysaccharides serve as specific recognition sites for regulation of
biological interactions. Yet only a few defined sequence motifs are
known2, perhaps the best example being the ATIII-binding
pentasaccharide responsible for the anticoagulant activity of
pharmaceutical heparin. This is in part due to technical limita-
tions in the structural analysis of the large heterogenous HS
chains, which is generally limited to compositional analysis of
disaccharide components obtained after exhaustive enzymatic
digestions3. Disaccharide analysis provides important “building
block” analysis of sulfation and acetylation of the disaccharide
units within a HS chain. However, this analysis does not provide
insight into larger bioactive motifs, typically consisting of 4–10
monosaccharide units. Partial digestion and isolation of larger
bioactive oligosaccharide structures (<dp10) is possible with
considerable effort, but heterogeneity often prevents complete
characterization4,5. A handful of tetrasaccharides (out of around
5000 theoretical structures) have been confidently characterized
since the number of isomeric structures is limited at this size6–9.
The heterogeneity of larger oligosaccharide structures (>dp4)
impose significant challenges in complete sequencing of isomers,
and even with NMR10, chemical modification11–13, and enzy-
matic deconvolution14 <20 structures have been fully sequenced.
Separation of isomeric structures is the main limitation for
sequencing larger oligosaccharide fragments. Ion mobility mass
spectrometry (IMMS) of glycans has demonstrated the ability to
characterise isomeric arrangements of glycan building blocks
(mannose, galactose, etc.), but also connectivity (glycosidic bond
linkage, sialic acids) and configuration (α and β anomers)15–18.
GAGs possess a linear sequence with no branching, and con-
nectivity is singular to the GAG family. However, GAGs pose
different challenges for IMMS analysis. GAG chain complexity is
a result of heterogeneity from sulfation and epimerisation, and
extended linear units. Preliminary results from our lab and others
have shown that IMMS is a promising strategy for the gas phase
separation of isomeric GAG oligosaccharide structures18–24.
Here we present a method coined Shotgun Ion Mobility Mass
Spectrometry Sequencing (SIMMS2) that relies on distinct IMMS
features of smaller fragments (dp4-10) obtained by limited
digestion and with reconstruction of overlapping fragments to
characterize larger sequences (Fig. 1). We take advantage of a
library of defined standards to build unique IMMS features that
enable us to obtain unambiguous sequence information on both
validated standards and unknown natural HS saccharides, and
also reveal structure-activity information on FGF-inhibitory HS
hexasaccharides. The SIMMS2 sequencing method thus opens up
detailed studies of bioactive motifs, aimed at deepening under-
standing of HS structure-function relationships and potentially
permitting strategies to discover HS-based therapeutics.
Results
Assembling a library of HS standards. HS is composed of a
repeating uronic acid and glucosamine disaccharide unit, the
uronic acid exists as either β-D-glucuronic acid (GlcA) or its
epimer α-L-iduronic acid (IdoA) and can be modified with a
sulfate at the C2 position, the glucosamine contains a N-sulfate
(NS) or N-acetyl group (NAc) and can be modified with a sulfate
on the C6 and rarely the C3 position. These modifications create
acetylated, transition (both acetylated and sulfated) and sulfated
domains (Fig. 1a). A library of standards representing features
found in heparin and HS (including NS/NAc, 2O-/6O/3O-sulfa-
tion (2S/6S/3S) and IdoA/GlcA) was collected. This library
encompasses a set of disaccharides isolated from heparinase-
digested HS, complemented by more extended oligosaccharide
structures produced by both chemoenzymatic25–28 and chemical
synthesis29–31. The final library included nine disaccharides, ten
tetrasaccharides, six hexasaccharides, six octasaccharides, two
nonasaccharides and two decasaccharides, in total providing
35 standards (#1–35), and a further standard (#36) described
later (See Supplementary Table 1). Whilst containing a number of
structural permutations (including NS/NAc, 2S/6S/3S, and IdoA/
GlcA), this initial library was designed to be sufficiently complex
to test our hypothesis that a library of defined standards can be
used to develop a sequencing strategy for larger HS oligo-
saccharides by IMMS (Fig. 1b–d).
IMMS separated standards display distinct characteristics.
Since we and others have shown that IMMS can resolve HS
saccharide isomers as large as octasaccharides19,20,22,23, we rea-
soned that it would have significant utility for HS sequencing in
concert with the library of standard oligosaccharides. In IMMS
molecular ions are transported through a gas-filled cell aided by a
weak electric field, where they are separated according to their
mass, charge, size and shape, which enables the differentiation of
isomers. From the resulting arrival time distributions (ATDs),
drift times can be extracted for individual components. When
measured under controlled conditions, drift times can be used to
calculate the collision cross section (CCS) values, a structural
property related to the rotationally averaged area of a given ion.
CCSs are generally given in units of ångström squared (Å2) and
serve as molecular descriptors that can be stored in databases and
used for the identification of analytes32. Depending on the uti-
lized IMMS technique, CCSs can be directly calculated from the
applied instrumental parameters as performed here (for details
see Methods) or obtained from calibration33. The resulting CCS
values derived from the 36 HS standards (#1–#36) and their
fragments (See Supplementary Tables 1 and 2) demonstrated the
ability of IMMS to distinguish between intact structures, different
sized fragment ions, charge states and isomeric structures (See
Supplementary Table 2).
Disaccharides—The disaccharide ΔUA-GlcNAc (#1) displayed
the smallest CCS of 112Å2, compared to disaccharide ΔUA2S-
GlcNS3S6S (#29) displaying the largest CCS value of 150Å2.
Isomeric structures ΔUA-GlcNAc6S (#2) and ΔUA2S-GlcNAc
(#7) displayed different CCS values of 121 Å2 and 124 Å2
respectively (Fig. 2a), with ΔUA-GlcNS6S (#4) and ΔUA2S-
GlcNS (#5) at CCS values of 123Å2 and 124Å2, respectively (See
Supplementary Tables 1 and 2).
Tetrasaccharides—Among the ten defined tetrasaccharides (#9–
#15, and #30–#32) in the library; four are homogenous or
heterogenous tetrasaccharides containing GlcA-GlcNAc6S and
IdoA-GlcNAc6S, two are heterogenous tetrasaccharides containing
GlcA/IdoA-GlcNS6S, and the seventh tetrasaccharide is GlcA-
GlcNS6S-IdoA2S-GlcNS6S-R1. The last three tetrasaccharides con-
tain 3O-sulfation correlating to the ATIII binding sites in porcine
and bovine heparin, including ΔUA-GlcNS-IdoA2S-GlcNS3S (#30),
ΔUA-GlcNS6S-GlcA-GlcNS3S6S (#31), and ΔUA-GlcNAc6S-GlcA-
GlcNS3S6S (#32). GlcA and IdoA are isomeric structures that
cannot be distinguished using MS/MS alone. The homogenous
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structures GlcA-GlcNAc6S-GlcA-GlcNAc6S-R1 (#9) and IdoA-
GlcNAc-IdoA-GlcNAc6S-R1 (#10) can be distinguished by IMMS
(Fig. 2b) with the homogenous GlcA tetrasaccharide (#9)
displaying a CCS value of 214 Å2 and IdoA tetrasaccharide
(#10) displaying a CCS value of 242 Å2 (See Supplementary
Tables 1 and 2). The heterogenous mixtures GlcA-GlcNAc6S-
IdoA-GlcNAc6S-R1 (#11) and IdoA-GlcNAc6S-GlcA-GlcNAc6S-
R1 (#13) displayed CCS values of 232 Å2 and 245 Å2, respectively
(See Supplementary Tables 1 and 2). Thus, the non-reducing end
GlcA from the heterogenous tetrasaccharide structure (#11)
displayed a more compact CCS, similar to the CCS observation in
the homogenous GlcA tetrasaccharide (#9). The non-reducing
IdoA from the heterogenous tetrasaccharide (#13) displayed a
more extended structure closer in CCS to the homogenous IdoA
tetrasaccharide (#10) structure than the homogenous GlcA
tetrasaccharide. Crucially, all four isomeric structures (#9, #10,
#11 and #13) had distinct CCSs. The heterogenous GlcA-
GlcNS6S-IdoA-GlcNS6S-R1 (#12) and IdoA-GlcNS6S-GlcA-
GlcNS6S-R1 (#14) tetrasaccharides were also distinguished, with
CCS values of 236 Å2 and 234 Å2, respectively (See
Supplementary Tables 1 and 2). As observed for the disacchar-
ides, the N-sulfate group generates a more compact structure
compared to saccharides with the N-acetyl groups, likely due to
the formation of a hydrogen bond between the N-sulfate oxygens
and the neighboring uronic acid34,35. The 2O-sulfate containing
tetrasaccharide GlcA-GlcNS6S-IdoA2S-GlcNS6S-R1 (#15) dis-
played a CCS value of 239 Å2, which was 3 Å2 larger than the
same structure without the 2O-sulfate (#12), confirming that the
N-sulfate is a dominating feature for the three-dimensional
structure (See Supplementary Tables 1 and 2). The 3O-sulfated
tetrasaccharides corresponding to the ATIII sites in porcine
ΔUA-GlcNS-IdoA2S-GlcNS3S (#30) and ΔUA-GlcNS6S-GlcA-
GlcNS3S6S (#31) displayed CCS values of 228 Å2 and 229 Å2
respectively. Whilst the tetrasaccharide corresponding to the
ATIII site in bovine heparin ΔUA-GlcNAc6S-GlcA-GlcNS3S6S
(#32) displayed a CCS value of 234 Å2.
Hexasaccharides to decasaccharides—Six hexasaccharides
were tested. The structure GlcA-GlcNS6S-IdoA-GlcNS6S-GlcA-
GlcNS6S-R1 (#16) is a disaccharide extension of one of the tested
tetrasaccharides (#14) and displayed a CCS value of 259 Å2.
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Fig. 1 Graphic depiction of the SIMMS2 strategy for de novo sequencing of HS saccharides. a Heparin and HS contain variant domains including
unmodified acetylated domains (with high levels of GlcNAc residues), transition domains (GlcNAc and GlcNS containing residues), and sulfated domains
(high levels of GlcNS and O-sulfation). A library of shorter oligosaccharide standards were generated. b Illustration of MS and MS/MS to provide mass and
the ability of ion mobility mass spectrometry (IMMS) to provide a third dimension that distinguishes isomers with collision cross section (CCS) values.
c The availability of MS, MS/MS, and IMMS data from a library of known standards (a, b) then allows a strategy for unambiguous sequencing of undefined
oligosaccharides based on comparison with standards. d Illustration of the iterative loop process for expansion of the CCS dataset necessary to further
develop the SIMMS2 strategy.
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The two homogenous isomeric hexasaccharide structures
GlcNAc6S-[GlcA-GlcNAc6S]2-GlcA-R2 (#17) and GlcNAc6S-
[IdoA-GlcNAc6S]2-IdoA-R2 (#18) displayed distinctly different
CCS values of 297 Å2 and 292 Å2, respectively (See Supplemen-
tary Table 2). Structures G-GlcNS6S-G-GlcNS6S-I2S-GlcNS6S-
R1 (#33) and G-GlcNS6S-G-GlcNS3S-I2S-GlcNS6S-R1 (#34) are
isomeric displaying CCS values of 280 Å2 and 282 Å2 respec-
tively. Structure G-GlcNS6S-G-GlcNS3S6S-I2S-GlcNS6S-R1
(#35) displayed a CCS value of 328 Å2.
Furthermore, we tested six octasaccharide structures
GlcNAc6S-[UA-GlcNAc6S]3-UA-R2 (#19– #24) that were either
homogenous with GlcA or IdoA residues, or heterogenous with
two GlcA and two IdoA residues. All these isomeric octasacchar-
ides are also distinguishable based on their distinct CCS values
(Fig. 2c and See Supplementary Tables 1 and 2). Whether a GlcA
or IdoA was next to the methoxyphenyl glycoside tag appeared to
affect the octasaccharide structure, with the GlcA-R on the
reducing end displaying a more extended structure than the
IdoA-R on the reducing end.
Two decasaccharides with homogenous disaccharide structures
GlcNAc6S-[IdoA-GlcNAc6S]4-IdoA-R2 (#27) and GlcNAc6S-
[GlcA-GlcNAc6S]4-GlcA-R2 (#28) were also distinguished with
CCS values of 536 Å2 and 524 Å2, respectively (Fig. 2d and See
Supplementary Table 2). Finally, we also found that two
nonasaccharides GlcA-GlcNS-GlcA-GlcNS-IdoA-GlcNS-GlcA-
GlcNS-GlcA-R3 (#25) and GlcA-GlcNS-GlcA-GlcNS-IdoA2S-
GlcNS-GlcA-GlcNS-GlcA-R3 (#26) differing only in 2O-sulfate
on the iduronic acids can be distinguished based on their CCS
values of 437 Å2 and 441 Å2, respectively.
Fragmentation of defined standards. The tetra- to dec-
asaccharides standards were subjected to fragmentation in the
trap cell of the mass spectrometer prior to separation in the
IMMS cell (See Supplementary Tables 3–51). This process
resulted in unique CCS values for each fragment ion where
homogenous IdoA B fragment ions (as defined by Domon and
Costello nomenclature36) resulted in more extended structures,
compared to homogenous GlcA B fragment ions (See Supple-
mentary Tables 3–51). In contrast, the hexa- to decasaccharides
with a nitrophenyl tag next to the IdoA/GlcA affected the
structural conformation, with IdoA Y product ions resulting in a
more compact structures compared to that of GlcA. A compar-
ison of B ions with GlcNAc6S or GlcNS6S showed that the NS
group resulted in a more compact structure (See Supplementary
Tables 3–18). Importantly, data obtained on internal fragments
from standards demonstrates the utility of single larger standards
to provide an extended set of CCS data values.
Development of a HS sequencing method—SIMMS2. While MS
and MS/MS alone do not enable unambiguous sequencing of
HS chains, our IMMS studies on the library of HS standards
demonstrated that IMMS could, firstly, distinguish HS structures
with different lengths up to decasaccharides, secondly, determine
disaccharide composition and order, and thirdly, distinguish
many isomeric structures. These collective abilities provide the
necessary data for complete structural identification of a large
number of important structures. We therefore hypothesized
that with sufficient information on fragmentation patterns and
CCS values from relevant standards, it would be possible to
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Fig. 2 Drift tube ion mobility separation (DTIMS) of isomeric HS standards. Intact HS standards were subjected to DTIMS to define collision
cross section (CCS) values. Variant degrees of separation were observed for (a), Disaccharides ΔUA-GlcNAc6S (#2) and ΔUA2S-GlcNAc (#7).
b Tetrasaccharides GlcA-GlcNAc6S-GlcA-GlcNAc6S-R1 (#9) and IdoA-GlcNAc6S-IdoA-GlcNAc6S-R1 (#10), where R1 is (CH2)5NH2. c Octasaccharides
GlcNAc6S-[IdoA-GlcNAc6S]3-IdoA-R2 (#19) and GlcNAc6S-[GlcA-GlcNAc6S]3-GlcA-R2 (#20), where R2 is C7H7O. d Decasaccharides GlcNAc6S-
[IdoA-GlcNAc6S]4-IdoA-R2 (#27) and GlcNAc6S-[GlcA-GlcNAc6S]4-GlcA-R2 (#28), where R2 is C7H7O. Full details of structures and CCS values
are provided in Supplementary Tables 1 and 2.
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unambiguously sequence unknown HS structures using data from
overlapping standards in a shotgun IMMS strategy—designated
SIMMS2.
To test this hypothesis, we used SIMMS2 to sequence the
hexasaccharide GlcA-GlcNS6S-IdoA-GlcNS6S-GlcA-GlcNS6S-R1
(#16) (Fig. 3). This approach exploits data from two tetrasacchar-
ides GlcA-GlcNS6S-IdoA-GlcNS6S-R1 (#12) and IdoA-GlcNS6S-
GlcA-GlcNS6S-R1 (#14) that represent all the possible mono-
saccharides contained in this hexasaccharide. Tetrasaccharide #12
generated CCS of B2 135 Å2 and B3 160 Å2 matching the CCS data
B2 135 Å2 and B3 160 Å2 from the hexasaccharide (#16),
confirming that the reducing ends were identical. Tetrasaccharide
#14 generated CCS of Y2 156 Å2 and Y3 213 Å2, matching with Y2
156 Å2 and Y3 213 Å2 from the hexasaccharide #16 confirming
that the non-reducing ends are identical (Fig. 3, and See
Supplementary Tables 4 and 6 display the full set of B, Y, C, and
Z ions). In addition, with the aid of CCS values of fragments ions
created by loss of a sulfate group from the two tetrasaccharides #12
and #14, we were able to sequence the hexasaccharide structure
#16 (See Supplementary Fig. 1 and See Supplementary Tables 28,
29 and 31).
In another example the structures of a nonamer (#25) and the
nonamer with a single 2O-sulfate (#26) were compared by
SIMMS2 (Fig. 4a and See Supplementary Tables 15–16)
demonstrating that this strategy could determine the position of
the single 2O-sulfate on the IdoA residue in nonasaccharide #26.
This supports the hypothesis that SIMMS2 has the potential to
serve as a method for sequencing extended glycosaminoglycan
structures.
Applying SIMMS2 to define ATIII and FGF-regulatory epi-
topes. It is generally observed that the majority of biological
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Fig. 3 Using the SIMMS2 method for sequencing a hexasaccharide. Overlaying two tetrasaccharide standard structures (#12 and #14) provides complete
sequence coverage of the hexasaccharide (#16). Each structure was fragmented in the trap of the mass spectrometer and analyzed using drift tube ion
mobility mass spectrometry (DTIMS), resulting in accurate collision cross section (CCS) values. A comparison of overlapping fragment ions displayed the
same CCS value between the two tetra- and hexasaccharides, providing a three-dimensional (MS, MS/MS and IMMS) sequencing method. a–f The
hexasaccharide displays the DTIMS data to be determined. g, h Tetrasaccharide #12 displayed CCS values from B ions; B2—135 Å2 and B3—160 Å2
matched CCS values observed in the hexasaccharide (a–c). i, j Tetrasaccharide #14 displayed CCS values from Y ions; Y2 156 Å2 and Y3 213 Å2 matched
the CCS values observed in the hexasaccharide (d–f).
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interactions of HS chains are conferred by motifs within the range
of 4–10 monosaccharide residues. The classic high affinity
antithrombin III binding site responsible for the anticoagulant
activity in pharmaceutical heparin is an important example;37,38
therefore CCS values were determined for the enzymatically
depolymerized natural structures (#29–#32) and synthesized
structures (#33–35) that correlated with the porcine and bovine
ATIII binding sites (See Supplementary Tables 19 to 25). SIMMS2
was used to sequence isomeric structures #33 and #34 (See
Supplementary Table 1) that differed only in the presence of
either a 6O-sulfate or a 3O-sulfate on a single glucosamine residue
(See Supplementary Fig. 2). B fragment ions from #33 and #34
were distinguishable: the B4 fragment ion of the 6O-sulfated
isomer (#33) has a CCS value of 225 Å2, whereas the B4 fragment
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Fig. 4 MS2 sequencing of two 9mer saccharides. HS structures #25 and #26 were fragmented in the trap and separated through IMMS to create a
defined set of CCS values for each fragment. IMMS of fragments (a) represent B ion fragments from #25, and #26, indicating that the 2O-sulfate is on the
IdoA at position 5. Fragment ions from B/Y/C/Z are displayed in Supplementary Tables 15 and 16. b Radar chart illustration of BaF3 cell activation
and inhibition assays of HS structures #25 and #26. Activation (cell proliferation) assays were performed with fibroblast growth factor 1 (FGF1) or FGF2
(1 ng/mL) and standards #25/26. Heparin (3 μg/mL) was used as positive control, while FGF1 or FGF2 alone was used as negative control. Inhibition
assays were performed with the same compounds (3 μg/mL) in the presence of a sub-maximal dose of heparin (0.1 μg/mL). Cell proliferation results were
expressed as a percentage of heparin activity set as 100%. Data for panel b are presented as mean ± standard deviation, n= 3. Source data are provided as
a Source Data file.
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of the isomer carrying 3O-sulfation (#34) has a CCS value of
220 Å2 (See Supplementary Fig. 2 and Supplementary Tables 23
and 24). This data clearly demonstrates the ability of SIMMS2 to
determine structures containing 3O-sulfate groups.
In addition, we used FGF1 and FGF2 regulation as a relevant
model to demonstrate sequencing capabilities for natural isolated
HS structures. We used BaF3 cell assays39 to evaluate activation
and inhibition of FGFs by HS compounds. First, we validated the
assay with heparin and the nonamer compounds #25/26, which
interestingly showed that the single 2O-sulfate group introduced
in #26 provides weak partial FGF2 activation, while neither
structure showed inhibitory activity (Fig. 4b).This is noteworthy
since previous results demonstrated that NS and 2OS are required
for FGF2 binding, while 6OS is required for optimal promotion of
FGF2 cellular signaling40,41. The nonasaccharide #26 lacks 6OS
and yet partially promotes FGF2 signaling, demonstrating the
utility of complete characterization of sequences by SIMMS2 in
deciphering cues for FGF bioactivities. We then obtained HS by-
products from pharmaceutical heparin production42, and used
limited heparinase III digestion to produce a range of oligosac-
charide size fractions, which were initially separated by size
exclusion chromatography (SEC). The dp8 and dp6 fractions were
further separated through strong anion exchange (SAX)-HPLC
and selected fractions were tested for bioactivity in the BaF3 assay
(See Supplementary Fig. 3a–b). Only the late eluting dp8 subfrac-
tions (more highly sulfated) induced FGF1 and FGF2 activation
(See Supplementary Fig. 3a–b); however, we were unable to
separate these fractions further into single entities due to low
abundance and high heterogeneity of these fractions. In contrast,
the dp6 fractions separated nicely into single oligosaccharides, and
two of these (b1 and b3) showed substantial FGF2 inhibitory
activity (See Supplementary Fig. 3b). The two inhibitory dp6
fractions were separated further by cetyltrimethylammonium-SAX
(CTA-SAX)43, and the purity assessed by MS and disaccharide
analysis, confirming that each represented a single hexasaccharide
structure designated #HS1 (b1) and #HS2 (b3) (See Supplementary
Fig. 4a–c).
Employing the SIMMS2 method and taking disaccharide analysis
into account, the potential hexasaccharide structures were limited
and sequences for #HS1 and #HS2 could be provisionally assigned
as ΔUA-GlcNS-IdoA2S-GlcNS-UA-GlcNAc and ΔUA-GlcNS-
IdoA2S-GlcNS6S-UA-GlcNAc6S, respectively (See Supplementary
Tables 52–69). Both proposed hexasaccharides display the same
non-reducing end (ΔUA-GlcNS-IdoA2S), and our IMMS data
confirmed that the first three non-reducing monosaccharides
indeed had the same CCS values (Fig. 5 and See Supplementary
Tables 59 and 68). The current standard library we employed is
necessarily limited to a subset of HS structures. To expand the
library of standards to include saccharides containing a 2O-sulfate
and a carbon-carbon double bond, we performed enzymatic
digestion of the nonamer standard #26 (with one 2O-sulfate
group), which provided the 7mer standard #36 (See Supplementary
Table 1) with a single 2O-sulfate. The SIMMS2 method was applied
to the ATIII tetrasaccharide #30, septsaccharide #36 and the
hexasaccharides #HS1 and #HS2 with a set of MS, MS/MS and CCS
values for each ΔUA-GlcNS-IdoA2S containing structure (See
Supplementary Tables 20, 26, 59, and 68). The CCS fragment ion
values from standard #36 were compared to the HS purified
hexasaccharide #HS1 (Fig. 5a and See Supplementary Tables 26 and
59), and the CCS data for B1, B2, and B3, B4 were the same in both
structures (71, 110, 162 and 201Å2, respectively; Fig. 5a and See
Supplementary Tables 26 and 59). This resulted in unambiguous
sequencing of hexasaccharide #HS1 and assignment of the sequence
as ΔUA-GlcNS-IdoA2S-GlcNS-GlcA-GlcNAc. A comparison of
#36, and #HS1 with #HS2 revealed that the B4 exhibited different
CCS values demonstrating the position of the predicted 6O-sulfate
groups and thus assigning the hexasaccharide structure of #HS2 as
ΔUA-GlcNS-IdoA2S-GlcNS6S-GlcA-GlcNAc6S (Fig. 5a, See Sup-
plementary Fig. 4c, and Tables 26, 59, and 68). A comparison of
tetrasaccharide #30 (from the ATIII binding site) to #HS2
confirmed B1, B2, and B3 fragment ions. The B4 ion of #30 and
#HS2 are isomers, with the former containing a 3O-sulfate and a
CCS value of 218 Å2 and the latter a 6O-sulfate with a CCS of 225
Å2 (Fig. 5 and See Supplementary Tables 20 and 68). We retested
the homogenous #HS1 and #HS2 hexasaccharides in the BaF3 cell
assay and found that they inhibit FGF2-dependent cell proliferation
with similar IC50 values of 638 and 566 nM, respectively (Fig. 5b).
The #HS1 and #HS2 hexasaccharides differ in only 6O-sulfation.
Previous studies have shown that 2O-sulfate is required for FGF2
binding, 6O-sulfate is additionally required for receptor activation,
although the detailed structural requirements for binding versus
activation is poorly understood39,41. However, as discussed above
we found that the 9mer standard #25 was unable to activate FGF2,
whereas in contrast the modified 9mer standard #26 with only a
single 2O-sulfate group sequenced by SIMMS2 displayed partial but
significant activation of FGF2 (Fig. 4b). A decasaccharide contain-
ing two 6O-sulfate groups was previously shown to have FGF2
inhibitory activity39, and our results demonstrate two smaller
hexasaccharides with none or two 6O-sulfate groups that exhibit
similar inhibitory activity. It is thus clear that the mere presence of
2O-sulfate and 6O-sulfate is not enough to drive regulation of FGF2
activity, and further studies are now justified to pursue the detailed
features of FGF-regulatory HS motifs, and will clearly be facilitated
by SIMMS2 methodology.
Discussion
The SIMMS2 method presented here relies on the resolving
power of IM to define IMMS features of smaller fragments (dp4-
10), and the reconstruction of overlapping fragments to char-
acterize larger sequences. It was identified that both odd and even
fragments are informative for SIMMS2 sequencing. This method
provides a substantial step forward in enabling direct sequencing
of HS saccharides. A key objective for the development of the
SIMMS2 strategy was to demonstrate sequencing of bioactive HS
motifs, since this has been a major bottleneck for advancement of
the field. We were able to demonstrate identification of hex-
asaccharide inhibitors with both 2O-sulfate and 6O-sulfate groups
which were notably selective for FGF2 versus FGF1, suggesting
the possibility of developing FGF-specific regulatory compounds.
We also exploited SIMMS2 to sequence an enzymically modified
9mer and showed that the addition of a single 2OS group con-
ferred partial activation of FGF2 (but not FGF1), despite lacking
any 6O-sulfation. This illustrates the utility of SIMMS2 for
defining structure-activity relationships for GAG saccharides and
emphasize its potential for the discovery of bioactive motifs with
pharmacological potential44–46.
SIMMS2 is a methodology relying on access to accurate CCS
values from standards, and while we demonstrated proof-of-
concept for sequencing HS through synthetic standards, further
development of SIMMS2 for complete analysis of all HS structures
will require access to a larger library of standards, generation of a
comprehensive CCS dataset, and improved strategies to isolate
and obtain homogeneous and heterogenous oligosaccharides.
Separation of isomeric glycans in some cases is possible, whereas
some isomeric glycans display similar CCS values47. In the present
study, the same phenomenon was observed, and is a recognized
limitation of IM/MS methodology in its current form. Thus, to
ensure correct oligosaccharide sequence identification, a compar-
ison of multiple CCS fragment values should be performed, and
the interpretation should include information from MS/MS and
disaccharide analysis. We anticipate further extension to other
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simpler GAGs will also be possible using a similar strategy as
suitable defined standards become available. Recent advances in
chemical30,31 and chemoenzymatic25–28 synthesis of GAG sac-
charides are providing expanding resources of structures to sup-
port building such standards and CCS datasets. Purification of
GAG oligosaccharides from tissues with current chromatography
methods is notoriously challenging due to the complex mixtures
obtained from such heterogenous sources. However, an emerging
source for standards may be cell lines with engineered capacities
for producing limited subsets of GAG features3,48, which should
simplify separation and isolation of homogeneous and hetero-
genous oligosaccharides. In particular, the GAGOme method
employing the robust Chinese hamster ovary (CHO) cell line to
engineer and produce specifically restricted repertoires of GAGs
with distinct features can help reduce complexities. These CHO
cells can also be used to produce distinct GAGs on secreted
proteins or by metabolic priming on glycosides, which may offer
unique access to defined standards required for developing the
SIMMS2 method.
A further aspect for expanding utility of the SIMMS2 method is
interpretation and analysis of spectra for HS and potentially other
GAG saccharides. Proteomics software packages perform poorly
with GAG spectra, since they commonly use averaging algorithms
of monoisotopic peaks and charge states. However, solutions are
beginning to emerge49,50. For example, Hogan et al.49 uses a
library of every possible theoretical fragment of a GAG saccharide
for each charge state and compares the theoretical isotopic dis-
tribution with observed spectral patterns. Data sharing provides
the resources for the development of improved algorithms for
GAG analysis, and our dataset from 36 oligosaccharides are
publicly available in UniCarbDR51 under MIRAGE guidelines52.
These resources will require continuous updating and expansion,
and they should be allied with effective software development.
Generation of sequence data on expanding numbers of HS sac-
charides, and links to relevant protein targets, will also provide
important information to support molecular modelling53 and
interaction studies54 which will aid in defining their mechanisms
of action in biological regulation.
The principles of SIMMS2 sequencing rely on the generation of
accurate CCS values and the resolving power of IMMS instru-
ments. The linear drift tube (DT)IMS employed here is the only
IMMS technique that enables the direct determination of accurate
CCSs without a need for a calibration procedure. Oligosaccharide
CCS values in this study were determined using a single DTIMS
instrument. Reproducibility, uncertainty and instrument varia-
bility has been addressed previously in an interlaboratory study55.
For fatty acids and metabolites an average error of 0.27 ± 0.18%
and 0.44 ± 0.28% was observed. Peptides and proteins showed the
largest error with the stepped field method, 0.53 ± 0.44% and
0.68 ± 0.36%, respectively. Our CCS data from 36 defined oligo-
saccharide structures can now be applied as calibrants to deter-
mine CCS values on other IMMS instruments, potentially
including traveling wave (TW)IMS, trapped (T)IMS and cyclic (c)
IMS. Moreover, the utility to distinguish isomers relies on the
IMMS resolving power, which can be expected to continue to
improve with advances in instrumentation, and this could help
alleviate this current limitation of the methodology. For example,
if the CCS of two isomeric ions differ by 2%, a resolving power of
64 (corresponding to a plate number of 22 500) is required to
separate them by DTIMS with a peak-to-peak resolution of 0.75.
SIMMS2 as a concept is entirely compatible with other MS labs, as
state-of-the-art commercial and custom-built DTIMS instru-
ments can achieve the required resolving power. Furthermore,
current developments in cIMS devices working with traveling
waves enable capabilities of achieving much higher levels of
resolving power, heralding immense potential for advances in
IMMS-based de novo sequencing strategies for HS and
other GAGs.
Whilst sequencing bioactive HS motifs is the most pressing
need, and is now enabled by the use of the SIMMS2 strategy,
intact HS chains are large, heterogenous, and composed of
multiple bioactive motifs. Defining more details of sequences of
intact HS chains remains a future challenge in which SIMMS2
may make a contribution. Only one example of intact GAG chain
sequencing has been reported56, where a short CS chain on the
proteoglycan bikunin with only 4O-sulfation was sequenced. A
second attempt was applied on the short DS chains on decorin57;
significant heterogeneity was observed and isomeric structures
were unresolved, but partial information on chain length and
level of sulfation was acquired. Nevertheless, we envision that
limited digestion of HS or GAG chains with multiple site-specific
enzymes will generate unique sets of partially overlapping frag-
ments that can be separated and then sequenced by SIMMS2;
overlaps of such fragments may enable assembly in a similar
manner to the shotgun sequencing approaches used in genomics
and proteomics. This could ultimately lead to insights into
domain structures and higher order arrangements of intact HS
and other GAG chains.
In summary, SIMMS2 is a shotgun method which enables
direct and unambiguous sequencing of HS oligosaccharides
through assembly of overlapping fragments. The method alle-
viates previous limitations imposed by the isomeric nature of
many HS saccharides, and we envision SIMMS2 being further
developed and expanded to enable sequencing of all types of GAG
oligosaccharides. Its application should accelerate decoding the
informational codes that underpin their functional versatility and
promise significant advances in their biomedical exploitation.
Methods
Materials and reagents. All chemicals were of analytical or HPLC grade purity
from Sigma (Gillingham, UK) or VWR (Lutterworth, UK) unless otherwise stated.
Disaccharide standards 1–8 were from Iduron (Manchester, UK), HS from Intel-
liHep (Liverpool, UK) and heparinases from IBEX (Montreal, Canada). Chemically
synthesized structures were produced as described31. Structure (#36) was produced
chemoenzymatically as described25. HS-2-O-sulfotransferase was expressed in
Origami B(DE3) cells (Novagen) and purified by chromatography as described58.
Chemical synthesis of standards. For the synthesis of standards desired building
blocks were prepared following reported procedures and assembled employing
modular approach31,59. The levulinoyl (Lev) esters of the sequences were removed
by treatment with hydrazine acetate, and subjected to O-sulfation using sulfur
trioxide/pyridine complex in DMF, followed by Fmoc removal with triethylamine/
dichloromethane (1/4, v/v). The methyl esters and acetates were saponified with
H2O2 and LiOH in THF. Next, the azide groups of the compounds were reduced
under Staudinger conditions using PMe3/THF (1.0 M), and the resulting amines
were N-sulfated, employing a sulfur trioxide/pyridine complex in MeOH in the
presence of Et3N and NaOH. The target structures were obtained by hydrogena-
tion, over Pd/C in a mixture of tBuOH/H2O (1/1, v/v) to cleave the protecting
group of the linker followed by further hydrogenation over Pd(OH)2/C to remove
the benzyl ethers, and finally purified by SEC over a P-2 column. All final struc-
tures were characterized by NMR spectroscopy and high resolution MS.
Preparation of 3O-sulfated di- and tetrasaccharide standards. The 3-O-sul-
fated disaccharide and 3-O-sulfated tetrasaccharide standards were prepared from
corresponding oligosaccharides after heparin lyases digestion as described pre-
viously60. Four 3-O-sulfated standards were used in this study, including ΔUA2S-
GlcNS3S6S, ΔUA-GlcNS-IdoA2S-GlcNS3S, ΔUA-GlcNS6S-GlcA-GlcNS3S6S, and
ΔUA-GlcNAc6S-GlcA-GlcNS3S6S. To prepare ΔUA2S-GlcNS3S6S disaccharide
standard, a synthetic octasaccharide with a structure of GlcNAc6S-GlcA-GlcNS6S-
IdoA2S-GlcNS3S6S-IdoA2S-GlcNS6S-GlcA-pNP (pNP represents p-nitrophenyl
group) was incubated with a mixture of heparin lyase I, II, and III in 50 mM
phosphate buffer pH 7.0 at 37 oC overnight. The ΔUA2S-GlcNS3S6S disaccharide
was purified by a Q-Sepharose column. The structure of ΔUA2S-GlcNS3S6S dis-
accharide standard was confirmed by electrospray ionization mass spectrometry
(ESI-MS) and by NMR as described60. To prepare ΔUA-GlcNS-IdoA2S-GlcNS3S,
ΔUA-GlcNS6S-GlcA-GlcNS3S6S, and ΔUA-GlcNAc6S-GlcA-GlcNS3S6S, three
different octasaccharide substrates with the structures of GlcNAc-GlcA-GlcNS-
IdoA2S-GlcNS3S-IdoA2S-GlcNS-GlcA-pNP, GlcNAc-GlcA-GlcNS6S-GlcA-
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GlcNS3S6S-IdoA2S-GlcNS6S-GlcA-pNP, and GlcNAc-GlcA-GlcNAc6S-GlcA-
GlcNS3S6S-IdoA2S-GlcNS6S-GlcA-pNP, respectively, were subjected to heparin
lyases digestion. Each tetrasaccharide was purified by Q-Sepharose, and the
structure was confirmed by ESI-MS and NMR60.
CCS measurements. Drift tube (DT)IMS and a helium buffer gas (HE) was used
to directly calculate DTCCSHe, designated as CCS (drift velocity of ions across
the cell is proportional to mobility). CCS of standards was performed on a
Synapt HDMS instrument modified with a linear drift tube IM cell as
described61,62, allowing determination of CCS values without calibration. Mass
Lynx V4.1 software (Waters) is used to operate the instrument and save data
files. Samples were measured at 0.05 µM in water/acetonitrile (50/50 v/v). Oli-
gosaccharides were ionized using nano-electrospray ionization (nESI) and Pd/Pt
or gold-coated borosilicate capillaries fabricated in-house. Mass spectra were
acquired in negative ion mode with a capillary voltage at 0.70 kV. Standard #10
was analyzed under soft and harsh source conditions, and demonstrated that the
determined CCS value was unchanged (See Supplementary Fig. 5). To obtain
product ion mobility data and produce comparable CID data for each isomer,
MS/MS was performed on selected ions in the trap cell of the instrument at 3, 8,
and 18 V (with argon as collision gas). CCS values were determined using the
stepped-field method, i.e., by plotting the arrival times (centroid of the best-fit
Gaussian) as a function of reciprocal drift voltages. Correlation coefficient (R2)
of the linear fits were typically ≥0.9999. ATDs were recorded at eight different
voltages ranging from 50 to 120 V. Each given CCS value is the average of two to
four independent measurements with deviations generally around 0.5%. Drift
times were extracted and CCSs calculated using software developed in-house or
manually using origin. Drift times were extracted manually where peak broad-
ening, split peaks or peak shoulders were evident. The algorithm for processing
ion-mobility data (Aprid) was written in-house and used for CCS calculation in
an automated fashion. Details about the code can be found in the code avail-
ability section.
Expression of 2O-sulfotransferase. The maltose binding protein (MBP)-2O-
sulfotransferase is a fusion protein was created using a pMAL-c2x vector (New
England Biolabs). The MBP was truncated at the Asn-367 residues and the 2OST
contained a mutation at E359A. The linker region encodes three alanine residues
(A368–A370) and contained a NotI site for cloning. The catalytic domain of
chicken 2OST (D69–N356) was cloned into the vector by using the NotI and
BamHI sites. The MBP-2OST was expressed in Origami B(DE3) cells (Novagen).
The cells were grown in LB medium and induced using isopropyl-β-D-thioga-
lactopyranoside (ITGP). Cells were left to grow on a shaker at 37 oC or overnight at
18 oC. Cells were pelleted and resuspended in 25 mM Tris (pH 7.5), 500 mM NaCl,
and 1 mM DTT. Sonication was used to lyse the cells. The MBP-2OST expressed
fusion protein was purified through an amylose resin (New England Biolabs) and
eluted from the beads using maltose58.
Generation of a 9-mer HS standard with 2O-sulfation. The 9mer standard #25
(500 µg) (See Supplementary Table 1) was incubated with 5 mU 2O-sulfo-
transferase in 100 mM PAPS, 50 mM MES, pH 7 at 30oC overnight. After heat
inactivation (98 oC, 4 min) products were separated by SAX-HPLC on a ProPac
PA1 column (4.6 mm × 250 mm, 5 µm bead size, Dionex) using a NaCl gradient
(0–1.4 M NaCl in HPLC grade water). Product with addition of a single 2O-sulfate
was observed at 30% yield; this 9mer+ 2O-sulfate (#26) was digested further with
heparinase II at 1 mU/mg to generate standard #36.
Pure bioactive hexasaccharide structures isolated from HS. HS (500 mg)
was dissolved in 900 µL of lyase buffer (100 mM sodium acetate, 10 mM calcium
acetate) and incubated with Heparinase I (0.5 mU/mg) at 37 oC, with aliquots
(300 µL) taken at 2, 4, and 8 h and heat inactivated. The aliquots were pooled and
separated by SEC using preparation grade Superdex 30 beads (15 mm × 170 cm,
bead size 34 µm – GE Healthcare) on an Akta FPLC system with isocratic elution
in 0.5 M NH4HCO3 (0.5 mL/min; 232 nm). Fractions containing HS of similar
dp were pooled and repeatedly freeze-dried using HPLC grade water to remove
NH4HCO3. Dp8 and dp6 SEC fractions were selected and separated by SAX-
HPLC (ProPac PA1) as described above using a 0–1.4 M NaCl gradient. The
two main fractions were desalted and separated by VSCTA-SAX on a cetyl-
trimethylammonium derivatized C18 column (4.6 mm × 250 mm, 5 µm bead size
– Sigma) using a gradient of 0–1.5 M NH4HCO3, as described43. Each fraction
was dried on a speed vac (Thermo Scientific) and subjected to DTIMS and
compositional analysis.
Compositional analysis. HS fractions digested with 0.1 mU each of heparinases I,
II, and III were incubated at 30 oC for 24 h, followed by HPLC on a Propac PA1
column with a NaCl gradient (0–1M, 60 min) monitoring at 232 nm; peaks were
evaluated by comparison with authentic standards.
BaF3 FGF signaling assays. The activity of HS oligosaccharides with FGF1 and
FGF2 was determined using BaF3 cells transfected with FGFR1c (from David
Ornitz, Washington University, St. Louis)39,42. BaF3 cells (1 × 104 cells/well) were
plated into 96 well plates with recombinant FGF-1 or FGF-2 (1 ng/mL; R&D
Systems) and either heparin or oligosaccharides (3 µg/mL). After 72 h 5 μL/well of
5 mg/mL MTT was added and incubated for 4 h. Formazan product was solubilized
with 10% SDS/0.01 N HCl and quantified at 570 nm. For inhibition assays sub-
optimal heparin was added at 0.1 µg/mL, with oligosaccharides tested at 3 µg/mL
Data are presented as mean ± standard deviation, n= 3–9.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Materials are available on request to the authors. All data generated or analyzed during
this study are included in this article and/or associated Supplementary Information
Tables 1–69 and uploaded to UniCarbDR. The source data underlying Figs. 4b and 5d
and Supplementary Fig. 3b are provided as a Source Data file.
Code availability
The algorithm for processing ion-mobility data (Aprid) was written in-house and used
for CCS calculation in an automated fashion. It is implemented using Python 2.7 and can
be operated by the user through a graphic interface devised in PyQtDesigner. The main
goal of the script is to determine collision cross-sections (CCSs) for specific mass-to-
charge (m/z) ratios. For that purpose, the script follows the mathematical approach of
solving the Mason-Schamp equation. Details about the code and modules can be found
online via github: https://github.com/waschbaerlauch/CCS-Calculation.
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